Blocking Blog calprotectin elisa Elisa hama antibodies hmgb1 elisa iron assay Isotype p24 elisa Pcr pge2 elisa plc gamma 2 rna Serum tbars assay kit tdgf1 triglyceride assay upp1 Vector
Streptolysin O concentration and activity is central to in vivo phenotype and disease outcome in Group A Streptococcus infection
Group A Streptoccocus (GAS) is among the many most numerous of all human pathogens, accountable for a variety of medical manifestations, from delicate superficial infections akin to pharyngitis to severe invasive infections akin to necrotising fasciitis and sepsis.
The drivers of those completely different illness phenotypes aren’t recognized. The GAS cholesterol-dependent cytolysin, Streptolysin O (SLO), has properly established cell and tissue harmful exercise. We investigated the position of SLO in figuring out illness final result in vivo, by utilizing two completely different medical lineages; the not too long ago emerged hypervirulent outbreak emm kind 32.2 strains, which end in sepsis, and the emm kind 1.Zero strains which trigger septic arthritis.
Utilizing clinically related in vivo mouse fashions of sepsis and a novel septic arthritis mannequin, we discovered that the quantity and exercise of SLO was important in figuring out the course of an infection. The emm kind 32.2 pressure produced giant portions of extremely haemolytic SLO that resulted in speedy growth of sepsis.
Against this, the lowered focus and decrease haemolytic exercise of emm kind 1.Zero SLO led to translocation of micro organism from blood to joints. Importantly, sepsis related strains that have been attenuated by deletion or inhibition of SLO, then additionally translocated to the joint, confirming the important thing position of SLO in figuring out an infection area of interest.
Our findings show that SLO is vital to in vivo phenotype and illness final result. Cautious consideration needs to be given to novel remedy or vaccination methods that focus on SLO. While neutralising SLO exercise might cut back extreme invasive illness, it has the potential to advertise continual inflammatory circumstances akin to septic arthritis.
A longitudinal sampling research of transcriptomic and epigenetic profiles in sufferers with thrombocytopenia syndrome’
Extreme fever with thrombocytopenia syndrome (SFTS) is a novel tick-borne infectious illness attributable to a brand new kind of SFTS virus (SFTSV). Right here, a longitudinal sampling research is performed to discover the variations in transcript ranges after SFTSV an infection, and to characterize the transcriptomic and epigenetic profiles of hospitalized sufferers.
The outcomes reveal important modifications within the mRNA expression of sure genes from onset to restoration. Furthermore, m6A-seq reveals that sure genes associated with immune regulation could also be regulated by m6A.
Moreover the routine checks akin to platelet counts, serum ALT and AST ranges testing, distinct modifications in myocardial enzymes, coagulation perform, and irritation are properly correlated with the medical knowledge and sequencing knowledge, suggesting that medical practitioners ought to monitor the above indicators to trace illness development and information personalised therapy.
On this research, the transcript modifications and RNA modification might lend a contemporary perspective to our understanding of the SFTSV and play a major position within the discovery of medication for efficient therapy of this illness.
Optimising classification of Parkinson’s illness primarily based on motor, olfactory, neuropsychiatric and sleep options
Olfactory loss, motor impairment, anxiousness/despair, and REM-sleep behaviour dysfunction (RBD) are prodromal Parkinson’s illness (PD) options. PD threat prediction fashions sometimes dichotomize take a look at outcomes and apply probability ratios (LRs) to scores above and under cut-offs. We examine whether or not LRs for particular take a look at values might improve classification between PD and controls.
PD affected person knowledge on odor (UPSIT), attainable RBD (RBD Screening Questionnaire), and anxiousness/despair (LADS) have been taken from the Monitoring Parkinson’s research (n = 1046). For motor impairment (BRAIN take a look at) in PD circumstances, revealed knowledge have been supplemented (n = 87). Management knowledge (HADS for anxiousness/despair) have been taken from the PREDICT-PD pilot research (n = 1314).
UPSIT, RBDSQ, and anxiousness/despair knowledge have been analysed utilizing logistic regression to find out which gadgets have been related to PD. Gaussian distributions have been fitted to BRAIN take a look at scores. LRs have been calculated from logistic regression fashions or rating distributions. False-positive charges (FPRs) for specified detection charges (DRs) have been calculated.
Sixteen odours have been related to PD; LRs for this set ranged from 0.005 to 5511. Six RBDSQ and 7 anxiousness/despair questions have been related to PD; LRs ranged from 0.35 to 69 and from 0.002 to 402, respectively. BRAIN take a look at LRs ranged from 0.16 to 1311. For a 70% DR, the FPR was 2.4% for the 16 odours, 4.6% for anxiousness/despair, 16.0% for the BRAIN take a look at, and 20.0% for the RBDSQ.
Particular choices of (prodromal) PD marker options reasonably than dichotomized marker take a look at outcomes optimize PD classification. Such optimized classification fashions might enhance the power of algorithms to detect prodromal PD; nevertheless, potential research are wanted to analyze their worth for PD-prediction fashions.
Sleep issues in ache sufferers coming into tertiary ache care: the position of pain-related anxiousness, medicine use, self-reported ailments, and sleep issues
Continual ache and sleep issues regularly co-occur. Ache itself disturbs sleep, however different elements can also contribute to sleep issues in ache sufferers. This cross-sectional research of 473 sufferers (69.9% feminine, imply age 47 years) coming into tertiary ache administration in contrast usually sleeping ache sufferers with these having recurring sleep issues to find out the connection between ache and sleep.
Teams have been in contrast for ache and ache aetiology, pain-related anxiousness, childhood adversities, use of sleep and ache medicines, self-reported ailments, and sleep issues. Additional, the affiliation of pain-related anxiousness (cognitive anxiousness, escape/avoidance, worry, and physiological anxiousness) with extra disturbing sleep issues was investigated in the entire cohort.
The primary outcomes have been that these with sleep issues extra typically reported a number of well being circumstances than these sleeping usually (despair 31.6% vs 5.0%; angina pectoris 6.5% vs 0.0%; bronchial asthma 19.6% vs 1.7%; low again issues 55.1% vs 23.3%; joint illness apart from rheumatoid arthritis 32.3% vs 18.3%).
Accumulations of 5 or extra childhood adversities have been extra typically current in these with sleep issues. Stressed legs signs have been extra frequent in these with sleep issues than these sleeping usually (33.2% vs 11.7%). Sufferers having sleep issues reported extra use of sleep and ache medicines than these sleeping usually. Findings about pain-related anxiousness recommend physiological reactions as important elements for elevated sleep disturbances. These elements have to be addressed within the administration of the comorbidity of ache and sleep issues and analysis to grasp mechanisms in these is sorely wanted.
Regulation and Position of αE Integrin and Intestine Homing Integrins in Migration and Retention of Intestinal Lymphocytes throughout Inflammatory Bowel Illness
Concentrating on interactions between α4β7 integrin and endothelial adhesion molecule MAdCAM-1 to inhibit lymphocyte migration to the gastrointestinal tract is an efficient remedy in inflammatory bowel illness (IBD). Following lymphocyte entry into the mucosa, a subset of those cells expresses αEβ7 integrin, which is expressed on proinflammatory lymphocytes, to extend cell retention.
The elements governing lymphocyte migration into the intestinal mucosa and αE integrin expression in wholesome topics and IBD sufferers stay incompletely understood. We evaluated modifications in elements concerned in lymphocyte migration and differentiation inside tissues.
Each ileal and colonic tissue from lively IBD sufferers confirmed upregulation of ICAM-1, VCAM-1, and MAdCAM-1 on the gene and protein ranges in contrast with wholesome topics and/or inactive IBD sufferers. β1 and β7 integrin expression on circulating lymphocytes was comparable throughout teams.
TGF-β1 therapy induced expression of αE on each β7+ and β7– T cells, suggesting that cells coming into the mucosa independently of MAdCAM-1/α4β7 can grow to be αEβ7+ ITGAE gene polymorphisms didn’t alter protein induction following TGF-β1 stimulation.
Elevated phospho-SMAD3, which is immediately downstream of TGF-β, and elevated TGF-β-responsive gene expression have been noticed within the colonic mucosa of IBD sufferers. Lastly, in vitro stimulation experiments confirmed that baseline β7 expression had little impact on cytokine, chemokine, transcription issue, and effector molecule gene expression in αE+ and αE– T cells.
ARVCF - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL314639 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Arvcf ORF Vector (Rat) (pORF) |
|||
| ORF063700 | ABM | 1.0 ug DNA | EUR 607.2 |
ARVCF ORF Vector (Human) (pORF) |
|||
| ORF015835 | ABM | 1.0 ug DNA | EUR 486 |
Arvcf ORF Vector (Mouse) (pORF) |
|||
| ORF039132 | ABM | 1.0 ug DNA | EUR 607.2 |
ARVCF Protein Vector (Rat) (pPM-C-HA) |
|||
| PV254800 | ABM | 500 ng | EUR 1399.2 |
ARVCF Protein Vector (Rat) (pPB-C-His) |
|||
| PV254798 | ABM | 500 ng | EUR 1399.2 |
ARVCF Protein Vector (Rat) (pPB-N-His) |
|||
| PV254799 | ABM | 500 ng | EUR 1399.2 |
ARVCF Protein Vector (Rat) (pPM-C-His) |
|||
| PV254801 | ABM | 500 ng | EUR 1399.2 |
ARVCF Protein Vector (Human) (pPM-C-HA) |
|||
| PV063339 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV156528 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Human) (pPB-C-His) |
|||
| PV063337 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPB-N-His) |
|||
| PV063338 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPM-C-His) |
|||
| PV063340 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Mouse) (pPB-C-His) |
|||
| PV156526 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Mouse) (pPB-N-His) |
|||
| PV156527 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Mouse) (pPM-C-His) |
|||
| PV156529 | ABM | 500 ng | EUR 1278 |
ARVCF Protein Vector (Human) (pPB-His-MBP) |
|||
| PV324102 | ABM | 500 ng | EUR 973.2 |
ARVCF Protein Vector (Human) (pPB-His-GST) |
|||
| PV324103 | ABM | 500 ng | EUR 973.2 |
Arvcf - Rat shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL708611V | Origene Technologies GmbH | 500 ul each | Ask for price |
Arvcf - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL500142V | Origene Technologies GmbH | 500 ul each | Ask for price |
ARVCF - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|||
| TL314639V | Origene Technologies GmbH | 500 ul each | Ask for price |
ARVCF Protein Vector (Human) (pPM-N-D-C-HA) |
|||
| PV324104 | ABM | 500 ng | EUR 1216.8 |
ARVCF Protein Vector (Human) (pPM-N-D-C-His) |
|||
| PV324105 | ABM | 500 ng | EUR 1216.8 |
Arvcf sgRNA CRISPR Lentivector set (Rat) |
|||
| K7275001 | ABM | 3 x 1.0 ug | EUR 406.8 |
ARVCF sgRNA CRISPR Lentivector set (Human) |
|||
| K0129701 | ABM | 3 x 1.0 ug | EUR 406.8 |
Arvcf sgRNA CRISPR Lentivector set (Mouse) |
|||
| K4629501 | ABM | 3 x 1.0 ug | EUR 406.8 |
Arvcf - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR708611 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Arvcf sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K7275002 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K7275003 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K7275004 | ABM | 1.0 ug DNA | EUR 184.8 |
ARVD1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV719087 | ABM | 1.0 ug DNA | Ask for price |
ARVD1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV719091 | ABM | 1.0 ug DNA | Ask for price |
ARVD3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV719093 | ABM | 1.0 ug DNA | Ask for price |
ARVD3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV719097 | ABM | 1.0 ug DNA | Ask for price |
ARVD4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV719099 | ABM | 1.0 ug DNA | Ask for price |
ARVD4 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV719103 | ABM | 1.0 ug DNA | Ask for price |
ARVD5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|||
| LV719105 | ABM | 1.0 ug DNA | Ask for price |
ARVD5 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|||
| LV719109 | ABM | 1.0 ug DNA | Ask for price |
Arvcf - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR500142 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
ARVCF - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector |
|||
| TR314639 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
ARVCF siRNA |
|||
| 20-abx908260 | Abbexa |
|
|
ARVCF siRNA |
|||
| 20-abx908261 | Abbexa |
|
|
ARVCF sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K0129702 | ABM | 1.0 ug DNA | EUR 184.8 |
ARVCF sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K0129703 | ABM | 1.0 ug DNA | EUR 184.8 |
ARVCF sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K0129704 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K4629502 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K4629503 | ABM | 1.0 ug DNA | EUR 184.8 |
Arvcf sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K4629504 | ABM | 1.0 ug DNA | EUR 184.8 |
ARVD1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV719092 | ABM | 1.0 ug DNA | Ask for price |
ARVD3 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV719098 | ABM | 1.0 ug DNA | Ask for price |
ARVD4 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV719104 | ABM | 1.0 ug DNA | Ask for price |
ARVD5 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|||
| LV719110 | ABM | 1.0 ug DNA | Ask for price |
ARVCF Antibody |
|||
| E40PV468 | EnoGene | 50ul | EUR 395 |
|
Description: Available in various conjugation types. |
|||
CD Lentiviral Vector |
|||
| LV678 | ABM | 10 μg | EUR 950 |
Arv1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL704784 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
ARV1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL306559 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Arv1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL504228 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
ARVCF Rabbit pAb |
|||
| A19304 | Abclonal | 50μL | EUR 262.15 |
ARVCF siRNA (Human) |
|||
| MBS8202258-15nmol | MyBiosource | 15nmol | EUR 405 |
ARVCF siRNA (Human) |
|||
| MBS8202258-30nmol | MyBiosource | 30nmol | EUR 565 |
ARVCF siRNA (Human) |
|||
| MBS8202258-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
ARVCF siRNA (Mouse) |
|||
| MBS8215797-15nmol | MyBiosource | 15nmol | EUR 405 |
ARVCF siRNA (Mouse) |
|||
| MBS8215797-30nmol | MyBiosource | 30nmol | EUR 565 |
ARVCF siRNA (Mouse) |
|||
| MBS8215797-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
dCas9-KRAB Lentiviral Vector |
|||
| K203 | ABM | 10 ug | EUR 165 |
|
Description: N/A |
|||
Cas9 Nickase Lentiviral Vector |
|||
| K005 | ABM | 10 ug | EUR 135 |
|
Description: N/A |
|||
ARVD1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV719088 | ABM | 1.0 ug DNA | Ask for price |
ARVD3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV719094 | ABM | 1.0 ug DNA | Ask for price |
ARVD4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV719100 | ABM | 1.0 ug DNA | Ask for price |
ARVD5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|||
| LV719106 | ABM | 1.0 ug DNA | Ask for price |
Cas9 Nuclease Lentiviral Vector |
|||
| K002 | ABM | 10 ug | EUR 135 |
|
Description: N/A |
|||
dCas9-TET1CD Lentiviral Vector |
|||
| K096 | ABM | 10 µg, Titer: N/A | EUR 395 |
|
Description: N/A |
|||
dCas9-DNMT3A Lentiviral Vector |
|||
| K091 | ABM | 10 µg, Titer: N/A | EUR 395 |
|
Description: N/A |
|||
ARVD1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV719089 | ABM | 1.0 ug DNA | Ask for price |
ARVD1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV719090 | ABM | 1.0 ug DNA | Ask for price |
ARVD3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV719095 | ABM | 1.0 ug DNA | Ask for price |
ARVD3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV719096 | ABM | 1.0 ug DNA | Ask for price |
ARVD4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV719101 | ABM | 1.0 ug DNA | Ask for price |
ARVD4 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV719102 | ABM | 1.0 ug DNA | Ask for price |
ARVD5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|||
| LV719107 | ABM | 1.0 ug DNA | Ask for price |
ARVD5 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|||
| LV719108 | ABM | 1.0 ug DNA | Ask for price |
ARVCF Oxidase antibody |
|||
| 20R-2590 | Fitzgerald | 100 uL | EUR 599 |
|
Description: Guinea Pig polyclonal ARVCF Oxidase antibody |
|||
ARVCF Oxidase antibody |
|||
| MBS834889-01mL | MyBiosource | 0.1mL | EUR 975 |
ARVCF Oxidase antibody |
|||
| MBS834889-5x01mL | MyBiosource | 5x0.1mL | EUR 4235 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K7275005 | ABM | 3 x 1.0 ug | EUR 451.2 |
Lenti ORF clone of Arvcf (mGFP-tagged) - Mouse armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf) |
|||
| MR211321L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Green Kit. Baculovirus GFP vector. |
|||
| K20 | AB Vector LLC | 1 Kit | EUR 695 |
|
Description: Protein expression |
|||
Lenti ORF particles, ARVCF (mGFP-tagged) - Human armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF), 200ul, >10^7 TU/mL |
|||
| RC222598L2V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, ARVCF (mGFP-tagged) - Human armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF), 200ul, >10^7 TU/mL |
|||
| RC222598L4V | Origene Technologies GmbH | 200 µl | Ask for price |
ARVCF Polyclonal Antibody |
|||
| MBS9234455-01mL | MyBiosource | 0.1mL | EUR 415 |
ARVCF Polyclonal Antibody |
|||
| MBS9234455-5x01mL | MyBiosource | 5x0.1mL | EUR 1841 |
ARVCF Polyclonal Antibody |
|||
| BS65730 | Bioworld Biotech | 50ul | EUR 208 |
|
Description: Rabbit |
|||
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K0129705 | ABM | 3 x 1.0 ug | EUR 451.2 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K4629505 | ABM | 3 x 1.0 ug | EUR 451.2 |
ProGreen. Baculovirus GFP marker vector. |
|||
| A1 | AB Vector LLC | 25 ul | EUR 420 |
|
Description: Protein expression |
|||
Lenti ORF particles, ARVCF (Myc-DDK tagged) - Human armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF), 200ul, >10^7 TU/mL |
|||
| RC222598L1V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, ARVCF (Myc-DDK tagged) - Human armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF), 200ul, >10^7 TU/mL |
|||
| RC222598L3V | Origene Technologies GmbH | 200 µl | Ask for price |
pVL1393. General baculovirus plasmid vector. |
|||
| B1 | AB Vector LLC | 50 ul | EUR 340 |
|
Description: Protein expression |
|||
Lenti ORF particles, Arvcf (GFP-tagged) - Mouse armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf), 200ul, >10^7 TU/mL |
|||
| MR211321L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Cas9 Double Mutant Lentiviral Vector |
|||
| K012 | ABM | 10 ug | EUR 395 |
|
Description: N/A |
|||
Lenti ORF clone of Arvcf (Myc-DDK-tagged) - Mouse armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf) |
|||
| MR211321L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Human ARVCF ELISA KIT |
|||
| ELI-34376h | Nova Lifetech | 96tests | EUR 696 |
Mouse Arvcf ELISA KIT |
|||
| ELI-49351m | Nova Lifetech | 96tests | EUR 736 |
Mouse Arvcf ELISA Kit |
|||
| EF014236 | Nova Lifetech | 96tests | EUR 566 |
Human ARVCF ELISA KIT |
|||
| EF004632 | Nova Lifetech | 96tests | EUR 566 |
Lenti ORF particles, Arvcf (GFP-tagged ORF) - Rat armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf), 200ul, >10^7 TU/mL |
|||
| RR207946L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K7275006 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K7275007 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K7275008 | ABM | 1.0 ug DNA | EUR 200.4 |
Lenti ORF particles, Arvcf (Myc-DDK-tagged) - Mouse armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf), 200ul, >10^7 TU/mL |
|||
| MR211321L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF clone of Arvcf (mGFP-tagged ORF) - Rat armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf), (10 ug) |
|||
| RR207946L4 | Origene Technologies GmbH | 10 µg | Ask for price |
ARVP6125 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|||
| TL315355 | Origene Technologies GmbH | 5 µg/vial | Ask for price |
Mouse ARVCF shRNA Plasmid |
|||
| 20-abx969243 | Abbexa |
|
|
Human ARVCF shRNA Plasmid |
|||
| 20-abx950307 | Abbexa |
|
|
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K0129706 | ABM | 1.0 ug DNA | EUR 200.4 |
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K0129707 | ABM | 1.0 ug DNA | EUR 200.4 |
ARVCF sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K0129708 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K4629506 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K4629507 | ABM | 1.0 ug DNA | EUR 200.4 |
Arvcf sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K4629508 | ABM | 1.0 ug DNA | EUR 200.4 |
ARVCF (untagged)-Human armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF) |
|||
| SC315001 | Origene Technologies GmbH | 10 µg | Ask for price |
Luciferase-mCherry Lentiviral Vector (CMV) |
|||
| LV010138 | ABM | 1.0 μg | EUR 230 |
Human ARVCF Protein Lysate |
|||
| MBS137594-002mg | MyBiosource | 0.02mg | EUR 545 |
Human ARVCF Protein Lysate |
|||
| MBS137594-5x002mg | MyBiosource | 5x0.02mg | EUR 2225 |
Lenti ORF particles, Arvcf (Myc-DDK-tagged ORF) - Rat armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf), 200ul, >10^7 TU/mL |
|||
| RR207946L3V | Origene Technologies GmbH | 200 µl | Ask for price |
ESR1 Lentiviral Vector (Human) (pLenti-II) |
|||
| LV010008 | ABM | 1.0 ug DNA | EUR 379.2 |
Lenti ORF clone of Arvcf (Myc-DDK-tagged ORF) - Rat armadillo repeat gene deleted in velo-cardio-facial syndrome (Arvcf), (10 ug) |
|||
| RR207946L3 | Origene Technologies GmbH | 10 µg | Ask for price |
ARVCF Peptide - middle region |
|||
| MBS3247212-01mg | MyBiosource | 0.1mg | EUR 180 |
ARVCF Peptide - middle region |
|||
| MBS3247212-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
ARVCF (NM_001670) Human Over-expression Lysate |
|||
| LS000421 | BosterBio | 100ug | EUR 960 |
|
Description: Transient overexpression lysate of armadillo repeat gene deletes in velocardiofacial syndrome (ARVCF) |
|||
ARVCF Antibody - middle region |
|||
| MBS3222544-01mL | MyBiosource | 0.1mL | EUR 455 |
ARVCF Antibody - middle region |
|||
| MBS3222544-5x01mL | MyBiosource | 5x0.1mL | EUR 1995 |
ProEasy. Vector for easy construction of recombinant baculoviruses. |
|||
| A10S | AB Vector LLC | 25 ul | EUR 695 |
|
Description: Protein expression |
|||
pLenti-GFP Lentiviral Control Vector |
|||
| LTV-400 | Cell Biolabs | 100 µL | EUR 500 |
pLenti-GFP Lentiviral Control Vector |
|||
| MBS168202-01mL | MyBiosource | 0.1mL | EUR 660 |
pLenti-GFP Lentiviral Control Vector |
|||
| MBS168202-5x01mL | MyBiosource | 5x0.1mL | EUR 2795 |
ARVCF (GFP-tagged) - Human armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF) |
|||
| RG222598 | Origene Technologies GmbH | 10 µg | Ask for price |
ARVCF Rabbit Polyclonal Antibody |
|||
| 54612 | SAB | 100ul | EUR 439 |
ARVCF Rabbit Polyclonal Antibody |
|||
| MBS9467735-005mL | MyBiosource | 0.05mL | EUR 300 |
ARVCF Rabbit Polyclonal Antibody |
|||
| MBS9467735-01mL | MyBiosource | 0.1mL | EUR 390 |
ARVCF Rabbit Polyclonal Antibody |
|||
| MBS9467735-5x01mL | MyBiosource | 5x0.1mL | EUR 1610 |
pAcAB3. Baculovirus plasmid vector for expression of up to 3 proteins. |
|||
| B2 | AB Vector LLC | 50 ul | EUR 420 |
|
Description: Protein expression |
|||
pSMPUW-Neo Lentiviral Expression Vector |
|||
| VPK-213 | Cell Biolabs | 10 µg | EUR 505 |
pLenti-MCS Lentiviral Expression Vector |
|||
| LV000 | ALSTEM | 10 µg | EUR 416.5 |
pSMPUW-Neo Lentiviral Expression Vector |
|||
| MBS169522-001mg | MyBiosource | 0.01mg | EUR 665 |
pSMPUW-Neo Lentiviral Expression Vector |
|||
| MBS169522-5x001mg | MyBiosource | 5x0.01mg | EUR 2825 |
pAB-bee. Baculovirus plasmid vector for secreted and transmembrane proteins. |
|||
| B3 | AB Vector LLC | 50 ul | EUR 495 |
|
Description: Protein expression |
|||
pSMPUW-Puro Lentiviral Expression Vector |
|||
| VPK-212 | Cell Biolabs | 10 µg | EUR 505 |
pSMPUW-Puro Lentiviral Expression Vector |
|||
| MBS169521-001mg | MyBiosource | 0.01mg | EUR 665 |
pSMPUW-Puro Lentiviral Expression Vector |
|||
| MBS169521-5x001mg | MyBiosource | 5x0.01mg | EUR 2825 |
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| VPK-214 | Cell Biolabs | 10 µg | EUR 505 |
pSMPUW-MNDnLacZ Lentiviral Control Vector |
|||
| LTV-402 | Cell Biolabs | 10 µg | EUR 741.6 |
|
Description: Use this control vector to co-transfect along with lentivirus packaging vectors to make a recombinant control lentivirus. |
|||
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| MBS169523-001mg | MyBiosource | 0.01mg | EUR 665 |
pSMPUW-Hygro Lentiviral Expression Vector |
|||
| MBS169523-5x001mg | MyBiosource | 5x0.01mg | EUR 2825 |
ARVCF (Myc-DDK-tagged)-Human armadillo repeat gene deleted in velocardiofacial syndrome (ARVCF) |
|||
| RC222598 | Origene Technologies GmbH | 10 µg | Ask for price |
Human ARVCF knockout cell line |
|||
| ABC-KH1041 | AcceGen | 1 vial | Ask for price |
|
Description: Human ARVCF knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
ProFold-PDI. Baculovirus chaperone vector for expression of cysteine-rich proteins. |
|||
| A7 | AB Vector LLC | 25 ul | EUR 830 |
|
Description: Protein expression |
|||
Human ARVCF knockdown cell line |
|||
| ABC-KD1041 | AcceGen | 1 vial | Ask for price |
|
Description: Human ARVCF knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Human ARVCF Protein Lysate 20ug |
|||
| IHUARVCFPLLY20UG | Innovative research | each | EUR 361 |
|
Description: Human ARVCF Protein Lysate 20ug |
|||
TH Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV699655 | ABM | 1.0 ug DNA | EUR 818.4 |
TH Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV699659 | ABM | 1.0 ug DNA | EUR 818.4 |
SI Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV694363 | ABM | 1.0 ug DNA | EUR 3415.2 |
SI Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV694367 | ABM | 1.0 ug DNA | EUR 3415.2 |
MB Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV694681 | ABM | 1.0 ug DNA | EUR 616.8 |
MB Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV694685 | ABM | 1.0 ug DNA | EUR 616.8 |
T Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV639319 | ABM | 1.0 ug DNA | EUR 818.4 |
T Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV639323 | ABM | 1.0 ug DNA | EUR 818.4 |
F7 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV666001 | ABM | 1.0 ug DNA | EUR 818.4 |
F7 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV666005 | ABM | 1.0 ug DNA | EUR 818.4 |
FH Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV666085 | ABM | 1.0 ug DNA | EUR 818.4 |
FH Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV666089 | ABM | 1.0 ug DNA | EUR 818.4 |
F9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV667969 | ABM | 1.0 ug DNA | EUR 818.4 |
F9 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV667973 | ABM | 1.0 ug DNA | EUR 818.4 |
C6 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV673381 | ABM | 1.0 ug DNA | EUR 1626 |
C6 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV673385 | ABM | 1.0 ug DNA | EUR 1626 |
KL Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|||
| LV673531 | ABM | 1.0 ug DNA | EUR 1626 |
KL Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|||
| LV673535 | ABM | 1.0 ug DNA | EUR 1626 |
These findings recommend cell migration to the intestine mucosa could also be altered in IBD and α4β7–, and α4β7+ T cells might upregulate αEβ7 in response to TGF-β as soon as throughout the intestine mucosa.
